Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 2219-2228, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallemacq, P. E.
Right arrow Articles by Reding, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallemacq, P. E.
Right arrow Articles by Reding, R.

Clinical Chemistry, Vol 39, 2219-2228, Copyright © 1993 by American Association for Clinical Chemistry

FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects

PE Wallemacq and R Reding
Department of Clinical Biochemistry, University Hospital St. Luc, University of Louvain, Brussels, Belgium.

The macrolide immunosuppressant FK506 (tacrolimus) is a powerful and selective anti-T-lymphocyte agent that was discovered in 1984. This agent, isolated from the fungus Streptomyces tsukubaensis, has a mechanism of action similar to that of cyclosporine. Experimental data were first published in 1987, and clinical trials were started 2 years later in Pittsburgh. The drug has a potent hepatotrophic effect, which could explain its success in liver transplantation. Particularly encouraging results were obtained in liver allograft recipients, suggesting a lower risk/benefit ratio than with other immunosuppressants. However, recent data show that the drug is not devoid of toxicity (mainly nephrotoxicity), which should the percent the need for careful blood monitoring. Several methods of analysis have been described, some satisfactory, others inadequate for routine monitoring. There is still a lack of specific methods to determine routinely the parent drug concentrations in biological fluids for clinical pharmacokinetics purposes. Despite greater experience in therapeutic drug monitoring, the correlation between FK506 concentrations and efficacy or toxicity is still unclear. More investigations are required to better understand and determine the appropriate use of FK506 in organ transplantation and treating autoimmune diseases.


The following articles in journals at HighWire Press have cited this article:


Home page
 CVIHome page
J. Jussila, J. Pelkonen, V.-M. Kosma, J. Maki-Paakkanen, H. Komulainen, and M.-R. Hirvonen
Systemic Immunoresponses in Mice after Repeated Exposure of Lungs to Spores of Streptomyces californicus
Clin. Vaccine Immunol., January 1, 2003; 10(1): 30 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. D. MacFarlane, D. G. Scheller, D. L. Ersfeld, L. M. Shaw, R. Venkatarmanan, L. Sarkozi, R. Mullins, and B. R. Fox
Analytical Validation of the PRO-Trac II ELISA for the Determination of Tacrolimus (FK506) in Whole Blood
Clin. Chem., September 1, 1999; 45(9): 1449 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
U. C. Garg, G. Austin, C. Barnes, and M. Hamilton
Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II Assays
Clin. Chem., August 1, 1998; 44(8): 1783 - 1785.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. E. Wallemacq, T. Leal, T. Besse, J.-P. Squifflet, R. Reding, J.-B. Otte, J. Lerut, and A. Hassoun
IMx Tacrolimus II vs IMx Tacrolimus Microparticle Enzyme Immunoassay Evaluated in Renal and Hepatic Transplant Patients
Clin. Chem., October 1, 1997; 43(10): 1989 - 1991.
[Full Text]

Home page
 CLIN PEDIATRHome page
R. Steffen, R. Wyllie, M. Kay, K. Kyllonen, T. Gramlich, and R. Petras
Autoimmune Enteropathy in a Pediatric Patient: Partial Response to Tacrolimus Therapy
Clinical Pediatrics, May 1, 1997; 36(5): 295 - 299.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.